Real-World First-Line Maintenance Niraparib Monotherapy Use Following Chemotherapy Plus Bevacizumab: The SW1TCH Study
Rimel, Bobbie, Boyle, Tirza Areli Calderón, Burns, Sara, Lim, Jonathan, Hartman, John, Kalilani, Linda, Schilder, Jeanne M., Hurteau, Jean A., Golembesky, Amanda
Published in Oncology and therapy (01.09.2024)
Published in Oncology and therapy (01.09.2024)
Get full text
Journal Article
Patient Characteristics Associated with Time to Next Treatment in Patients with Ovarian Cancer Treated with Niraparib: The PRED1CT Real-World Study
Chase, Dana M., Shukla, Soham, Moore, Julia, Boyle, Tirza Areli Calderón, Lim, Jonathan, Perhanidis, Jessica, Hurteau, Jean A., Schilder, Jeanne M.
Published in Oncology and therapy (01.09.2024)
Published in Oncology and therapy (01.09.2024)
Get full text
Journal Article
2022-RA-708-ESGO Real-world assessment of patients with ovarian cancer who received niraparib as second-line maintenance therapy in the United States: did first-line maintenance approval change the patient profile for second-line maintenance therapy?
Backes, Floor, Calderón Boyle, Tirza Areli, Perhanidis, Jessica, Lim, Jonathan, Kalilani, Linda, Hurteau, Jean A, Golembesky, Amanda, Salani, Ritu
Published in International journal of gynecological cancer (20.10.2022)
Published in International journal of gynecological cancer (20.10.2022)
Get full text
Journal Article
197 What is the real-world risk of MDS/AML and other secondary primary malignancies in patients with epithelial ovarian cancer treated with niraparib maintenance treatment? Interim results from a regulatory safety study
Kommoss, Stefan, Tasca, Giulia, Areli Calderón Boyle, Tirza, Golembesky, Amanda, Schilder, Jeanne M, Malinowska, Izabela A, Ye, Guilan, Kuplast, Judi, Perhanidis, Jessica, Zeliku, Zoe, Alonso, Constanza Maximiano, Vorst, Maurice Van Der
Published in International journal of gynecological cancer (10.03.2024)
Published in International journal of gynecological cancer (10.03.2024)
Get full text
Journal Article
Characteristics and real-world outcomes of patients with epithelial ovarian cancer who received niraparib plus bevacizumab first-line maintenance therapy in the COMB1NE study
Thaker, Premal H, Areli Calderón Boyle, Tirza, Burns, Sara, Lim, Jonathan, Hartman, John, Kalilani, Linda V, Schilder, Jeanne M, Hurteau, Jean A, Golembesky, Amanda K
Published in International journal of gynecological cancer (07.09.2024)
Published in International journal of gynecological cancer (07.09.2024)
Get full text
Journal Article
Real-world treatment patterns among advanced HR+/HER2- breast cancer patients in the post-CDK4/6 inhibitor era: An analysis of administrative claims data
Boyle, Tirza Areli Calderón, Shukla, Soham, Powers Happ, Lindsey, Zheng, Shan, Gorsh, Boris
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
Epidemiology of adenoid cystic carcinoma in the United States
Boyle, Tirza Areli Calderón, St. Laurent, Samantha, Semus, Simon, Joseph, Nedra
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
Abstract A056: Development and application of an epithelial ovarian cancer-specific line of therapy algorithm using real-world data
Sweetnam, Connor, Boyle, Tirza Areli Calderón, Burns, Sara, Perhanidis, Jessica, Rioth, Matthew, Matsuno, Rayna K
Published in Cancer research (Chicago, Ill.) (04.03.2024)
Published in Cancer research (Chicago, Ill.) (04.03.2024)
Get full text
Journal Article